How antibody sugar tags shape lung immune responses
Regulation Of Lung Immunity By Antibody Glycosylation
Researchers want to see if different sugar decorations on antibodies change lung inflammation during infections like COVID-19 and influenza.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11241142 on NIH RePORTER |
What this research studies
This work looks at how tiny sugar marks on IgG antibodies change the way immune complexes talk to lung cells during respiratory infections. Scientists will use mice engineered to carry human antibody receptors and will expose them to SARS-CoV-2 or influenza to compare antibody glycoforms such as fucosylation and sialylation. They will measure viral levels, lung inflammation, and immune signals, and use molecular tools to trace which pathways drive harmful or protective responses. The team also compares their findings to patterns seen in people with different disease severities to link the lab work back to patients.
Who could benefit from this research
Good fit: People who had recent or past COVID-19 or influenza and are willing to provide blood or respiratory samples could be relevant for the human-sample comparisons in this research.
Not a fit: Patients without infection-driven lung inflammation or those seeking direct clinical treatment are unlikely to gain immediate benefit from this basic research.
Why it matters
Potential benefit: If these findings hold up, they could point to new biomarkers or treatments that limit harmful lung inflammation in COVID-19, influenza, and similar infections.
How similar studies have performed: Previous studies have shown that antibody glycosylation patterns track with disease severity and can alter immune effects, but using that knowledge to change lung outcomes in COVID-19 and influenza is relatively new.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Wang, Taia — Stanford University
- Study coordinator: Wang, Taia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.